The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection

AIDS

Volumn 15, Issue 9, 2001, Pages

  García, Felipe ^a,e   Plana, Montserrat ^a   Ortiz, Gabriel M ^b   Bonhoeffer, Sebastian ^c   Soriano, Alex ^a   Vidal, Carmen ^a   Cruceta, Anna ^a   Arnedo, Mireia ^a   Gil, Cristina ^a   Pantaleo, Giuseppe ^d   Pumarola, Tomás ^a   Gallart, Teresa ^a   Nixon, Douglas F ^b   Miró, José M ^a   Gatell, José M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e HOSPITAL CLÍNIC   (Spain)

Author keywords

Dynamics; HIV; Specific immunity; Structured treatment interruptions; Viral load

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; DRUG WITHDRAWAL; GENOTYPE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; PILOT PROJECTS; VIRAL LOAD;

EID: 0035876068     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200106150-00002     Document Type: Article

References (41)

1. Rapid turnover of plasma virions and CD4 lymphocytres in HIV-1 infection
2. Viral dynamics in human immunodeficiency viruis type I infection
3. HIV-1 dynamics in vivo: Virion clearance rate, infected cell lifespan and viral generation time
4. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
5. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidemia and diabetes mellitus: A cohort study
6. Metabolic abnormalities and use of HIV-1 protease inhibitors
7. How immune-based interventions can change HIV therapy
8. The challenge of immune control of immunodeficiency virus
9. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques
10. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
11. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques
12. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
13. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells
14. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
15. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
16. HIV-1 specific immune response in subjects who temporarely contain virus replication after discontinuation of HAART
17. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide
18. HIV-1 suppression by early treatment with hydroxyurea, didanosine and a protease inhibitor
19. Control of HIV despite the discontinuation of antiretroviral therapy
20. Immune control of HIV-1 after early treatment of acute infection
21. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
22. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiation of treatment
23. Lack of T-cell proliferative response to HIV-1 antigens after one year of HAART in very early HIV-1 disease
24. Strong human immunodeficiency virus-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy
25. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virustype 1 infection with combination antiretroviral therapy
26. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: The Spanish Earth-1 study
27. Comparison of immunological restoration and virological response in plasma, tonsillar tissue and cerebrospinal fluid in HIV-1 infected patients treated with double versus triple antiretroviral therapy in very early stages. The Spanish Earth-2 Study
28. Detection of low HIV-1 RNA levels in Plasma
29. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study
30. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption
31. Levels of human immunodeficiency virus type-1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
32. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversily correlated with HIV type I viral load in HIV type 1-infected long-term survivors
33. Antiretroviral therapy in adults. Updated recommendation of the International AIDS Society-USA panel
34. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy
35. The dacay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy
36. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
37. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes
38. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
39. Immunological benefits of antiretroviral therapy in very early stages of asymtomatic chronic HIV-1 infection
40. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)-propyl]adenina (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA
41. The role of antigen-independent persistence of memory cytotoxic T lymphocytes